Medicine

T. Poynard, P. Marcellin, Samuel S. Lee, C. Niederau, International Hepatitis Interventional Therapy Group

1998.10.31EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

DOI: 10.1097/00042737-199812000-00020

tlooto Summary

AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.

Abstract

Abstract is not available.

Citation format

POYNARD, T., et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis c virus. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10: 1063.